Medicare's $50 GLP-1 discount skips an estimated 5.9 million enrollees with treatable conditions

A KFF Health News investigation published Aug. 25, 2026 estimates that 5.9 million Medicare enrollees are shut out of the Medicare GLP-1 Bridge program's $50 monthly price because their charts already show a condition that FDA-approved GLP-1 drugs are cleared to treat ^[1][2]. Type 2 diabetes and moderate-to-severe obstructive sleep apnea are two examples. Those patients are returned to their Part D prescription drug plan, where the copay for a GLP-1 can reach $200 to $600 a month ^[1][2].

How the program works

The Bridge program is an 18-month demonstration that started in July and covers three products: Wegovy (semaglutide), the KwikPen version of Zepbound (tirzepatide), and the oral medicine Foundayo (orforglipron) ^[1][2]. Enrollees must have Medicare Part D coverage. A body mass index of 35 or higher generally qualifies a patient if a clinician prescribes the drug; people with a BMI of 27 to 34 can qualify when they also have certain conditions, including prediabetes or cardiovascular disease ^[1][2]. Prior authorization requests are submitted to a system run by a CMS contractor rather than to the enrollee's insurer ^[1][2].

The wrinkle sits in the eligibility rules. The $50 rate applies only when the drug is being used solely for weight loss. Once a qualifying condition that the FDA has already approved GLP-1s for appears in the record, the request is routed to Part D instead ^[1][2].

One patient's denial

Jeff La Marca, 68, of Basking Ridge, New Jersey, received a Zepbound prescription in January but could not cover the $750 monthly cost ^[1][2]. He applied to the pilot and was rejected, without an explanation of the reason, according to the reporting ^[1][2].

La Marca has severe obstructive sleep apnea, a BMI of 42, and says he is prediabetic, is at risk for stroke and has had quadruple heart bypass surgery. He believes his weight alone would have qualified him if not for the sleep apnea diagnosis. "I'm obese, morbidly obese, BMI 42," he said ^[1][2]. His insurer declined to answer detailed questions about his case ^[1][2].

Juliette Cubanski, who leads the Program on Medicare Policy at KFF, said the program "was designed to target those people who can't get GLP-1 coverage through Part D but would benefit from taking one for weight loss" ^[1][2].

The cost question

Cubanski has estimated that 3.8 million people meet the criteria. If one-quarter enroll and remain on treatment for the pilot's full 18 months, Medicare would spend roughly $3.3 billion; at three-quarters enrollment, the figure could climb to about $10 billion ^[1][2]. The federal government has not published its own projection ^[1][2]. Adding the 5.9 million who already have Part D access to GLP-1s would push costs higher still, the reporting says ^[1][2].

Officials describe a smooth start. CMS spokesperson Timothy Foster said most prior authorization requests have been finished in under 12 hours in the demonstration's opening weeks, which "has allowed thousands of eligible beneficiaries to access GLP-1 medications for weight loss at pharmacies nationwide" ^[1][2]. Chris Bond of the insurance trade group AHIP pointed to manufacturers' prices, "which they alone set and they alone can lower" ^[1][2].

Why it matters for patients

What a Medicare enrollee pays for a GLP-1 can hinge on what else is in the medical record. Someone with obesity and no other listed condition may pay $50 a month. Someone with obesity plus type 2 diabetes or moderate-to-severe sleep apnea is directed to Part D, where copays described in the reporting run $200 to $600 a month or more ^[1][2].

Reaching the pharmacy counter can itself take months. Taylor Lacy, a primary care physician at Sunflower Medical Group in Roeland Park, Kansas, said Medicare patients often must satisfy prior authorization and try cheaper alternatives first, a practice called step therapy, only to find the eventual copay unaffordable. "'Coverage' doesn't always mean 'affordable,'" she said ^[1][2]. Research on Medicare insurers' GLP-1 coverage has found rising out-of-pocket costs and prior authorization requirements in nearly all plans ^[1][2]. About 1 in 5 American adults have taken a GLP-1, and most say the drugs are hard to afford ^[1][2]. La Marca's prescription remains unfilled ^[1][2].

What happens next

The pilot runs 18 months from its July launch ^[1][2]. Whether Medicare will widen it to the 5.9 million people who already have GLP-1 coverage through Part D has not been announced ^[1][2].